104 related articles for article (PubMed ID: 38723771)
1. Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years.
Esteban R; Domínguez-Hernández R; Cantero H; Casado MÁ
Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723771
[TBL] [Abstract][Full Text] [Related]
2. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
Yun H; Zhao G; Sun X; Shi L
BMJ Open; 2020 Aug; 10(8):e035224. PubMed ID: 32819983
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
[TBL] [Abstract][Full Text] [Related]
7. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
Bwa AH; Nangia G; Win STS; Maung ST; Han KAW; Htar SS; Wine LY; Ko WW; Oo MP; Hlaing NKT; Palecki J; Loza BL; Win KM; Reddy R
J Clin Exp Hepatol; 2019; 9(3):283-293. PubMed ID: 31360020
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan.
Mushtaq S; Akhter TS; Khan A; Sohail A; Khan A; Manzoor S
Front Pharmacol; 2020; 11():550205. PubMed ID: 32982753
[TBL] [Abstract][Full Text] [Related]
9. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
Aliment Pharmacol Ther; 2024 May; ():. PubMed ID: 38695095
[TBL] [Abstract][Full Text] [Related]
10. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.
Graf C; D'Ambrosio R; Degasperi E; Paolucci S; Llaneras J; Vermehren J; Dultz G; Peiffer KH; Finkelmeier F; Herrmann E; Zeuzem S; Buti M; Lampertico P; Dietz J; Sarrazin C
JHEP Rep; 2024 Mar; 6(3):100994. PubMed ID: 38357421
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Chan J; Kim JJ; Barrett BK; Hamadeh A; Feld JJ; Wong WWL
J Viral Hepat; 2021 Feb; 28(2):260-267. PubMed ID: 33065774
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.
Esteban R; Domínguez-Hernández R; Martín-Escudero V; Casado MÁ
PLoS One; 2022; 17(12):e0278544. PubMed ID: 36454996
[TBL] [Abstract][Full Text] [Related]
14. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
15. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
16. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
